Chalcogen In The Six-membered Hetero Ring Patents (Class 514/90)
-
Publication number: 20100203110Abstract: The present invention relates to methods of treating a cancerous tumor in a subject comprising administering to the subject an effective amount of 3-bromopyruvate. The 3-bromopyruvate may be administered intraarterially directly to a tumor as a continuous intraarterial infusion. The present invention also relates to methods for identifying agents that inhibit type II hexokinase activity.Type: ApplicationFiled: December 17, 2007Publication date: August 12, 2010Applicant: The Johns Hopkins UniversityInventors: Jean-Francois Geschwind, Mustafa Vali
-
Publication number: 20100183581Abstract: This invention provides conjugates of therapeutic or active agents with melanotransferrin or with other ligands of a melanotransferrin receptor, melanotransferrin receptor modulators, and related compositions and methods for modulating blood-brain barrier transport by providing methods of screening and selecting such conjugates, ligands, and modulators in vitro and in vivo, and methods of use of such conjugates, modulators and ligands in diagnosis and the treatment of diseases, including particularly diseases of the central nervous system or lysosomal storage diseases.Type: ApplicationFiled: January 7, 2010Publication date: July 22, 2010Applicant: RAPTOR PHARMACEUTICAL INC.Inventors: Richard Beliveau, Michel Demeule, Joseph Yang, Malcolm L. Kennard, Reinhard Gabathuler
-
Publication number: 20100183587Abstract: The invention provides methods and compositions for minimizing, preventing, or treating damage to corneal nerves by administering to a subject with such damage or at risk of exposure to such damage a composition which blocks an activity of an IL-1 cytokine and/or an IL-17 cytokine.Type: ApplicationFiled: January 11, 2010Publication date: July 22, 2010Applicant: Schepens Eye Research InstituteInventors: Reza Dana, Mohammad Dastjerdi, Sunil Chauhan
-
Publication number: 20100183603Abstract: The present invention relates to pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a compound or pyrrolidine-2,5-dione compound of the present invention.Type: ApplicationFiled: June 19, 2008Publication date: July 22, 2010Applicant: ARQULE, INC.Inventors: Neil Westlund, Jason Hill, Mark A. Ashwell, Nivedita Namdev, Jianqiang Wang, Syed Ali
-
Publication number: 20100166699Abstract: The invention provides a combination comprising an ancillary compound (e.g.Type: ApplicationFiled: June 21, 2006Publication date: July 1, 2010Applicants: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Neil Thomas Thompson, Robert George Boyle, Ian Collins, Michelle Dawn Garrett, John Francis Lyons, Kyla Merriom Thompson
-
Publication number: 20100150844Abstract: 8-quinolinol (8Q) and derivatives thereof for use in the treatment of proliferative diseases such as cancer, in particular slow metabolizing quiescent cancer stem cells.Type: ApplicationFiled: July 30, 2007Publication date: June 17, 2010Applicant: The Johns Hopkins UniversityInventors: Ying Zhang, Jiangbing Zhou, Hao Zhang
-
Publication number: 20100143499Abstract: Compounds, compositions, and methods of using such compounds to modulate apoptosis including IAP antagonists are provided herein. Compositions including mimetics of the invention and, optionally, secondary agents, may be used to treat proliferative disorders such as, cancer and autoimmune diseases.Type: ApplicationFiled: July 24, 2007Publication date: June 10, 2010Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventor: Stephen M. Condon
-
Publication number: 20100143386Abstract: The present invention relates to Fibroblast-Growth Factor Receptor 4 (FGRF4) inhibitors for co-administration with a therapeutic procedure or/and agent for the prevention, alleviation or/and treatment of a hyperproliferative disorder, e.g. cancer, such as chemotherapy resistant cancer. Further, the present invention relates to a diagnostic procedure wherein expression status and/or polymorphisms of the FGFR4 gene are determined in a patient suffering from a hyperproliferative disorder, e.g. cancer. Based on the results of this determination and the status of the disorder to be treated a therapeutic protocol may be developed. Yet another subject of the present invention is a screening method.Type: ApplicationFiled: November 2, 2007Publication date: June 10, 2010Applicant: Max-Planck-Gesellschaft zur foerderung der Wissenschaften, e. V.Inventors: Axel Ullrich, Hans-Juergen Berger, Andreas Roidl
-
Publication number: 20100143295Abstract: The present invention relates to new quinazoline inhibitors of EGFR tyrosine kinase, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: December 4, 2009Publication date: June 10, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Patent number: 7732374Abstract: A fungicidal mixture comprising prothioconazole or its salts or adducts and at least one insecticide selected from the group consisting of fipronil, chlorpyrifos or thiamethoxam.Type: GrantFiled: July 17, 2007Date of Patent: June 8, 2010Assignee: BASF SEInventors: Eberhard Ammermann, Reinhard Stierl, Gisela Lorenz, Siegfried Strathmann, Klaus Schelberger, V. James Spadafora, Thomas Christen
-
Publication number: 20100135956Abstract: The present invention relates to new steroid modulators of progesterone receptor activity and/or glucocorticoid receptor activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: November 23, 2009Publication date: June 3, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Manouchehr Shahbaz
-
Publication number: 20100129350Abstract: We describe compounds of the following general formula (I): wherein X is fluorine or chlorine; Y is oxygen, sulfur, or an amino group; R is an amino, hydroxyl, sulfonamide, or carboxamide group or an N-monomethyl or N-dimethyl analog thereof; m is an integer from 2 to 6, and n is an integer from 0 to 2. The compounds may be used for treating certain cancers and autoimmune diseases.Type: ApplicationFiled: April 25, 2008Publication date: May 27, 2010Applicant: PROMETIC BIOSCIENCES INC.Inventors: Boulos Zacharie, Christopher Penney, Lyne Gagnon, Brigitte Grouix, Lilianne Geerts, Shaun D. Abbott
-
Publication number: 20100124544Abstract: The present invention relates to the crystalline forms of 2-allyl-1-[6-(I-hydroxy-1 methylethyl)pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one or a salt thereof, which are useful in the field of treatment of various cancers as a kinase inhibitor, especially as a Weel kinase inhibitor.Type: ApplicationFiled: April 22, 2008Publication date: May 20, 2010Inventors: Masashi Kawasaki, Hiroo Mizuno, Toshihiro Sakamoto, Kimimasa Suzuki, Arlene E. Mckeown
-
Publication number: 20100105636Abstract: There is provided a T-type calcium channel blocker that is a compound of formula (1), a pharmaceutically acceptable salt thereof or a solvate thereof: wherein Ar1 is phenyl group, pyridyl group, furyl group or 2,1,3-benzoxadiazol-4-yl group; nitrogen-containing hetero ring moiety is 1,4-dihydropyridine ring or pyridine ring; Z is a group of formula (2) or CO2R2; Ra and Rb are independently of each other C1-6alkyl group, ANR8R9, CH2OANR8R9, or the like; in case where the nitrogen-containing hetero ring moiety is 1,4-dihydropyridine ring, R1 is C1-6alkyl group, ANR8R9, AN(CH2CH2)2NR8, AN(CH2CH2)2O, AOR8 or benzyl group; R3 is hydrogen atom, C1-20alkyl group, ANR8R9, a group of formula or the like.Type: ApplicationFiled: January 4, 2010Publication date: April 29, 2010Applicant: Nissan Chemical Industries, Ltd.Inventors: Taiji FURUKAWA, Osamu Yamada, Hiroo Matsumoto, Toru Yamashita, Yukinori Masuda
-
Publication number: 20100087399Abstract: The present invention provides novel methods of combination therapy of ovarian cancer, pharmaceutical kits and combinations of 9-oxoacridine-10-acetic acid and/or salts and/or esters thereof with one or more chemotherapeutic agents. The proposed combination therapy is useful in enhancing the action of chemotherapeutic agents and their proliferative activity on human ovarian cancer cells.Type: ApplicationFiled: September 29, 2009Publication date: April 8, 2010Inventor: Kirill Gennadievich SURKOV
-
Publication number: 20100080756Abstract: CXCR3 agonists, including natural CXCR3 ligands, promote bone marrow regeneration, increase peripheral white blood cells, and increase survival if administered prior to treatment of a subject with chemotherapy or radiotherapy. Similar effects are obtained by administering an CXCR3 antagonists following chemotherapy radiotherapy. Compositions and methods are presented for the treatment of cancer and bone marrow diseases.Type: ApplicationFiled: September 23, 2009Publication date: April 1, 2010Inventors: Wei Han, Huili Lu, Di Xiang
-
Publication number: 20100074927Abstract: Microparticle carriers, particularly protein-encapsulated microbubbles, are used to deliver antiproliferative drugs to target sites in a subject. In particular, antirestenotic drugs are delivered to areas of vascular injury for treatment or prevention of hyperproliferative disease, e.g. stenosis, in blood vessels; and antineoplastic drugs are targeted to tumor sites.Type: ApplicationFiled: September 17, 2009Publication date: March 25, 2010Inventors: Patrick L. Iversen, Nicholas Kipshidze
-
Publication number: 20100061984Abstract: Methods of treating autoimmune disorders, coronary artery disease, allergy symptoms, allograft rejection sepsis/toxic shock are disclosed. Some methods comprise administering one or more regulatory compositions to activate the T suppressor cells by increasing the acetylation level and/or protein level of FOXP3 in combination with a T suppressor stimulus and/or an antigen. Some methods comprise administering one or more regulatory compositions to activate the T suppressor cells by increasing the acetylation level and/or protein level of FOXP3. Some methods comprise administering soluble GITR or antibodies that bind to GITR ligand. Methods of treating cancer, infectious diseases, and immune deficiency are also disclosed as are vaccination methods. The methods comprise administering one or more regulatory compositions to inactivate the T suppressor cells by reducing the acetylation level and/or protein level of FOXP3. Improved vaccines and vaccination methods are disclosed.Type: ApplicationFiled: January 22, 2007Publication date: March 11, 2010Applicants: The Trustees of the University of Pennsylvania, The Children's Hospital of PhiladelphiaInventors: Mark L. Greene, Sandra W. Saouaf, Bin Li, Hongtao Zhang, Wayne Hancock
-
Publication number: 20100029592Abstract: The present application describes deuterium-enriched fosaprepitant, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: August 4, 2009Publication date: February 4, 2010Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090318388Abstract: The present invention provides a method of hydroxylating or oxidizing a compound of interest in a subject (e.g., a cytotoxic oxazaphosphorine prodrug), by administering the compound of interest to the subject; and concurrently administering the subject a metalloporphyrin in an amount effective to hydroxylate or oxidize the compound of interest in the subject.Type: ApplicationFiled: November 6, 2007Publication date: December 24, 2009Applicant: DUKE UNIVERSITYInventors: Ivan Spasojevic, Michael O. Colvin, Ines Batinic-Haberle, Susan M. Ludeman, Michael P. Gamcsik
-
Patent number: 7635708Abstract: The present invention is based on the finding that activation of PPAR? plays a key role in inducing growth arrest and differentiation of certain actively proliferating cells. We show that administration of PPAR? agonists, such as thiazolidinedione ligands (TZDs), is effective both in vitro and in vivo at inhibiting the proliferation of such cells.Type: GrantFiled: December 19, 2002Date of Patent: December 22, 2009Assignee: Dana-Farber Cancer InstituteInventors: Bruce M. Spiegelman, Elisabetta Mueller, Pasha Sarraf, Soner Altiok, Peter Tontonoz, Samuel Singer
-
Publication number: 20090281063Abstract: The present invention is to provide means to treat breast cancer and/or mastitis by topically administering a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent and allowing them efficiently to arrive into the mammary gland. The present invention provides an iontophoretic preparation for treating breast cancer and/or mastitis which contains a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent as an active ingredient and has a donor to be applied on a nipple part for topical administration of the active ingredient from the nipple part to the mammary gland by application of electric potential.Type: ApplicationFiled: October 11, 2006Publication date: November 12, 2009Applicants: KOWA CO., LTD., TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATIONInventors: Toshio Inagi, Makoto Kanebako, Hiroshi Terada, Kimiko Makino, Masakazu Toi
-
Publication number: 20090192098Abstract: This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ROS) in vivo. The method may further comprise co-administering a second chemotherapeutic agent.Type: ApplicationFiled: November 21, 2008Publication date: July 30, 2009Applicant: OXIGENE, INC.Inventors: David Chaplin, Bronwyn G. Siim
-
Publication number: 20090170813Abstract: Hypophosphorous acid derivatives having Formula (I) wherein .M is a [C(R3,R4)]n1-C(E,COOR1,N(H,Z)) group, or an optionally substituted Ar—CH(COOR1,N(H,Z)) group, or an a, ?, or a ?, g-cyclic amino acid; .R1 is H or R, R being an hydroxy or a carboxy protecting group; .Z is H or an amino protecting group R?, benzyl oxycarbonyl, benzyl or benzyl substituted; .E is H or a C1-C3 alkyl, aryl, an hydrophobic group; .Type: ApplicationFiled: October 18, 2006Publication date: July 2, 2009Inventors: Francine Acher, Chelliah Selvam, Nicolas Triballeau, Jean-Philippe Pin, Hugues-Oliver Bertrand
-
Publication number: 20090136496Abstract: Provided herein are methods for identifying a subject afflicted with chronic lymphocytic leukemia who is responsive to treatment with a chemotherapeutic agent by detecting the presence or absence of at least one APOE4 allele in the subject, the presence of an APOE4 allele identifying the subject as responsive to the treatment. Also provided are methods of treating a subject afflicted with chronic lymphocytic leukemia, including administering an estrogenic agent, an androgen withdrawal agent, an apoE4 peptide or mimetic thereof, and/or a chemotherapeutic agent in an amount effective to treat said chronic lymphocytic leukemia. Methods of determining a prognosis for a patient diagnosed with chronic lymphocytic leukemia are also provided. In addition, methods for stratifying a subject into a subgroup of a clinical trial and methods for identifying a patient in a clinical trial of a treatment for chronic lymphocytic leukemia are herein provided.Type: ApplicationFiled: November 5, 2008Publication date: May 28, 2009Applicant: Duke UniversityInventors: J. Brice Weinberg, Warren J. Strittmatter
-
Publication number: 20090130097Abstract: The present invention relates to quinazolinone compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the quinazolinone compounds.Type: ApplicationFiled: June 19, 2008Publication date: May 21, 2009Applicant: ArQule, Inc.Inventors: Jifeng Liu, Syed M. Ali, Mark A. Ashwell, Ping Ye, Yousheng Guan, Shi-Chung Ng, Rocio Palma, Dan Yohannes
-
Publication number: 20090130229Abstract: The use of an arylidene 2-indolinone derivative for treating tumors involving Met, PDGF-R, FGF-RI, FGF-R3 or Kit tyrosine kinases, or a Ret oncoprotein which includes a MEN2-associated mutation is disclosed.Type: ApplicationFiled: November 13, 2008Publication date: May 21, 2009Applicants: Cell Therapeutics, Inc., Instituto Nazionale per lo Studio e la Cura dei TumoriInventors: Cinzia Lanzi, Giuliana Cassinelli, Giuditta Cuccuru, Marco A. Pierotti, Franco Zunino, Ernesto Menta
-
Publication number: 20090081155Abstract: The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.Type: ApplicationFiled: July 18, 2008Publication date: March 26, 2009Applicant: Medical College of Georgia Research Institute, IncInventors: David Munn, Andrew Mellor
-
Publication number: 20090053168Abstract: The invention provides compositions and methods for the treatment of B-cell proliferative disorders that employ an A2A receptor agonist or one or more PDE inhibitors. The methods and compositions may further include an antiproliferative compound.Type: ApplicationFiled: July 17, 2008Publication date: February 26, 2009Inventors: Richard Rickles, Margaret S. Lee
-
Publication number: 20090028850Abstract: Methods of prolonging survival of allotransplanted cells, tissues or organs are presented. These methods are directed to administering to the allotransplant recipient an inhibitor of complement activity together with one or more immunosuppressants. The inhibitor of complement activity is administered chronically. These methods have been determined to aid in preventing chronic rejection of allografts. These methods can additionally be used in cases in which the recipient has been presensitized to the allograft or in which there is an ABO mismatch between the allograft and the recipient.Type: ApplicationFiled: May 16, 2005Publication date: January 29, 2009Applicant: Alexion Pharmaceuticals, Inc.Inventors: Russell P. Rother, Hao Wang, Aili Lao
-
Publication number: 20090017009Abstract: Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin.Type: ApplicationFiled: March 4, 2008Publication date: January 15, 2009Inventors: Paula J. Bates, Donald M. Miller, John O. Trent, Xiaohua Xu
-
Patent number: 7468359Abstract: The present invention relates to compositions useful for treating or controlling disease states or conditions associated with zinc containing proteinases, especially metalloproteinases. The active ingredient in these compositions is an alpha-oxo- or alpha-thioxophosphonate of formula (I). Out of the phosphonates of formula (I), some are known and others are new. The novel compounds constitute another aspect of the invention.Type: GrantFiled: May 23, 2006Date of Patent: December 23, 2008Assignee: Yissum Research Develpment Company of the Hebrew University of JerusalemInventors: Eli Breuer, Reuven Reich, Claudio Salomon
-
Publication number: 20080279961Abstract: It is demonstrated in the present invention that G-quadruplex ligands can be used to both shorten telomeres and inhibit telomerase by causing telomere uncapping. The invention relates to compositions and methods of treating cancer stem cells comprising the administration of G-quadruplex ligands, such as 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4), which can effectively inhibit or reduce the growth of cancer stem cells. The invention also relates to a synergistic effect in inhibiting or reducing the growth cancer stem cells when a G-quadruplex ligand is combined with a mitotic spindle poison, such as paclitaxel, or other agents used in the treatment of cancer and disease. The invention also relates to RHPS4 inducing non-cancerous cell and non-cancerous stem cell proliferation.Type: ApplicationFiled: May 9, 2008Publication date: November 13, 2008Inventor: Angelika M. BURGER
-
Publication number: 20080269172Abstract: The present invention provides lysine based compounds of the formula; and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein R1 may be, for example, (HO)2P(O)—, (NaO)2P(O)—, alkyl-CO— or cycloalkyl-CO—, wherein X may be, for example, F, Cl, and Br, and wherein R2 and R3 are as defined herein.Type: ApplicationFiled: April 4, 2008Publication date: October 30, 2008Inventors: Brent Richard Stranix, Valerie Perron
-
Publication number: 20080253960Abstract: The present invention provides a non-naturally occurring lipoprotein nanoplatform (“LBNP”) comprising at least one cell surface receptor ligand; at least one lipoprotein; and at least one diagnostic agent and/or at least one therapeutic agent. In embodiments of the present invention, the cell surface receptor ligand is not a low-density lipoprotein receptor ligand and the cell surface receptor ligand is covalently bonded to the apoprotein. The present invention also provides pharmaceutical formulations comprising LBNPs and methods of making the LBNPs.Type: ApplicationFiled: April 1, 2005Publication date: October 16, 2008Applicant: The Trustees of the University of Pennsylvania Center for Technology TransferInventors: Gang Zheng, Jerry D. Glickson
-
Publication number: 20080242637Abstract: The present invention relates to a novel drug target in cancer therapy. More closely it relates to use of the cytochrome P450 enzyme CYP2W1 and its promoter as a drug target for cancer therapy. It also relates to screening methods for obtaining therapeutic agents for cancer therapy and to therapeutic agents comprising moieties showing binding affinity for CYP2W1 and moieties with cytotoxic/anti-cancer effect.Type: ApplicationFiled: March 11, 2008Publication date: October 2, 2008Inventors: Magnus Ingelman-Sundberg, Maria Karlgren, Alvin Gomez
-
Publication number: 20080242638Abstract: This invention relates to methods of inducing differential stress resistance in a subject with cancer by starving the subject for a short term, administering a cell growth inhibitor to the subject, or reducing the caloric or glucose intake by the subject. The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents.Type: ApplicationFiled: March 28, 2008Publication date: October 2, 2008Applicant: University of Southern CarliforniaInventor: Valter Longo
-
Publication number: 20080200436Abstract: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of ZD6474 in combination with androgen ablation; to a pharmaceutical composition comprising ZD6474 and an antiandrogen; to a combination product comprising ZD6474 and an antiandrogen for use in a method of treatment of a human or animal body by therapy; to a kit comprising ZD6474 and an antiandrogen; to the use of ZD6474 and an antiandrogen in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation.Type: ApplicationFiled: November 1, 2005Publication date: August 21, 2008Inventor: Stephen Robert Wedge
-
Publication number: 20080193448Abstract: The invention provides methods of treating cancer using a compound of formula (1) or a pharmaceutically acceptable salt thereof, particularly a malate salt, in combination with various additional therapeutic agents. The invention also provides therapeutic dosing regimens, using the compound of formula (1) and an additional therapeutic agent.Type: ApplicationFiled: May 4, 2006Publication date: August 14, 2008Applicant: PFIZER INC.Inventor: Charles M. Baum
-
Publication number: 20080119421Abstract: A process for treating a biological organism, comprising the steps in which a cell cycle arresting drug is administered to the organism to produce synchronized cells, the microtubules within the synchronized cells are stabilized by means of a microtubule stabilizing agent, and the synchronized cells with the stabilized microtubules are then contacted with mechanical vibrational energy.Type: ApplicationFiled: October 28, 2004Publication date: May 22, 2008Inventors: Jack Tuszynski, Howard J. Greenwald, Stephen H. Curry, Kendrick Goss
-
Patent number: 7354928Abstract: The present invention relates to small molecule antagonists of Bcl-2 family proteins such as Bcl-2 and/or Bcl-XL. In particular, the present invention provides non-peptide cell permeable small molecules (e.g., tricyclo-dibenzo-diazocine-dioxides) that bind to a pocket in Bcl-2/Bcl-XL that block the anti-apoptotic function of these proteins in cancer cells and tumor tissues exhibiting Bcl-2 protein overexpression. In preferred embodiments, the small molecules of the present invention are active at the BH3 binding pocket of Bcl-2 family proteins (e.g., Bcl-2, Bcl-XL, and Mcl-1). The compositions and methods of the present invention are useful therapeutics for cancerous diseases either alone or in combination with chemotherapeutic or other drugs.Type: GrantFiled: November 1, 2002Date of Patent: April 8, 2008Assignee: The Regents of the University of MichiganInventors: Shaomeng Wang, Dajun Yang, Istvan J. Enyedy
-
Patent number: 7345046Abstract: Heteroaryl-fused pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.Type: GrantFiled: May 21, 2004Date of Patent: March 18, 2008Assignee: Chiron CorporationInventors: Weibo Wang, Liana Marie Lagniton, Ryan N. Constantine, Matthew T. Burger
-
Patent number: 7268124Abstract: The invention provides novel pyrophosphate synthase inhibitors of formula I as well as compositions comprising such inhibitors and methods for their use.Type: GrantFiled: August 25, 2005Date of Patent: September 11, 2007Assignee: University of Iowa Research FoundationInventors: David F. Wiemer, Raymond J. Hohl
-
Patent number: 7205001Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.Type: GrantFiled: November 3, 2003Date of Patent: April 17, 2007Assignee: Polarx Biopharmaceuticals, Inc.Inventors: Ralph M. Ellison, Fred H. Marmelstein
-
Patent number: 7199111Abstract: The present invention provides aqueous Ifosfamide compositions and a process for their preparation, in which the compositions have a reduced toxicity over and above the concomitant use of the uroprotective agent, Mesna. Aqueous Ifosfamide compositions can be prepared at concentrations as high has 1,1000 mg/ml.Type: GrantFiled: December 2, 2003Date of Patent: April 3, 2007Assignee: Bharat Serums & Vaccines Ltd.Inventors: Gautam Vinod Daftary, Srikanth Annappa Pai, Sangeeta Hanurmesh Rivankar, Praveen Kumar Subbappa
-
Patent number: 7166611Abstract: A pharmaceutical composition contains an extract obtainable from a plant of the genus Trichocaulon or Hoodia containing an appetite suppressant agent having the formula (1). A process for obtaining the extract and a process for synthesizing compound (1) and its analogues and derivatives is also provided. The invention also extends to the use of such extracts and compound (1) and its analogues for the manufacture of medicaments having appetite suppressant activity.Type: GrantFiled: June 22, 2004Date of Patent: January 23, 2007Assignee: CSIRInventors: Fanie Retief Van Heerden, Robert Vleggaar, Roelof Marthinus Horak, Robin Alec Learmonth, Vinesh Maharaj, Rory Desmond Whittal
-
Patent number: 7163703Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.Type: GrantFiled: August 14, 2003Date of Patent: January 16, 2007Assignee: PolaRx Biopharmaceuticals, Inc.Inventors: Ralph M. Ellison, Fred H. Mermelstein
-
Patent number: 7045495Abstract: This invention provides methods for screening a modulating agent which when combined with antitumor therapeutic agent increases apoptosis in tumor cells. This invention also provides methods for screening antitumor therapeutic agents suitable for combination therapy with a protein kinase C inhibitors capable of potentiating apoptosis in tumor cells. This invention further provides different combination therapies comprising the specific protein kinase C inhibitors and the antitumor therapeutic agents.Type: GrantFiled: August 7, 2002Date of Patent: May 16, 2006Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Gary K. Schwartz, Anthony P. Albino
-
Patent number: 7038039Abstract: A desired isomer is selectively prepared by phosphorolyzing and isomerizing an anomer mixture of a 1-phosphorylated saccharide derivative while crystallizing one of the isomers to displace the equilibrium. Furthermore, using the action of a nucleoside phosphorylase, a nucleoside is prepared from the 1-phosphorylated saccharide derivative obtained and a base with improved stereoselectivity and a higher yield. This process is an anomer-selective process for preparing a 1-phosphorylated saccharide derivative and a nucleoside.Type: GrantFiled: February 13, 2001Date of Patent: May 2, 2006Assignee: Mitsui Chemicals, Inc.Inventors: Hironori Komatsu, Hirokazu Awano, Nobuyuki Fukazawa, Kiyoshi Ito, Ichirou Ikeda, Tadashi Araki, Takeshi Nakamura, Tamotsu Asano, Junya Fujiwara, Tomoyuki Ando, Katsutoshi Tsuchiya, Kyoko Maruyama, Hideki Umetani, Takahiro Yamauchi, Hitoki Miyake
-
Patent number: 6875451Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.Type: GrantFiled: October 15, 1998Date of Patent: April 5, 2005Assignee: PolaRx Biopharmaceuticals Inc.Inventors: Ralph M. Ellison, Fred H. Mermelstein